{"prompt": "['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'that the exposure of docetaxel increased 2.2-fold when it was coadministered with', 'ketoconazole, a potent inhibitor of CYP3A4. Protease inhibitors, particularly ritonavir,', 'may increase the exposure of docetaxel. Concomitant use of docetaxel and drugs that', 'inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. In patients', 'receiving treatment with docetaxel, close monitoring for toxicity and a docetaxel dose', 'reduction could be considered if systemic administration of a potent CYP3A4 inhibitor', 'cannot be avoided', '7.4.1.2 Abiraterone', 'Abiraterone is an inhibitor of the hepatic drug-metabolizing enzyme CYP2D6. In', 'a', 'CYP2D6 drug-drug interaction trial, the Cmax and AUC of dextromethorphan', '(CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively, when', 'dextromethorphan was given with abiraterone acetate 1,000 mg daily and prednisone 5', 'mg twice daily. Avoid coadministration of abiraterone acetate with substrates of', 'CYP2D6 with a narrow therapeutic index (e.g., thioridazine). If alternative treatments', 'cannot be used, exercise caution and consider a dose reduction of the concomitant', 'CYP2D6 substrate drug.', 'Abiraterone is also a substrate of CYP3A4. The effects of strong CYP3A4 inhibitors', '(e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir,', 'telithromycin, ritonavir, indinavir, nelfinavir, voriconazole) or inducers (e.g., phenytoin,', 'carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital) on the pharmacokinetics', 'of abiraterone have not been evaluated, in vivo. Avoid or use with caution, strong', 'inhibitors and inducers of CYP3A4 during abiraterone treatment.', '7.5', 'Duration of Therapy', 'Arm A: Patients will receive 6 cycles of docetaxel, given approximately every 3 weeks, in', \"addition to physician's choice ADT.\", \"Arm B: Patients will receive abiraterone continuously, in addition to physician's choice ADT,\", 'until disease progression.', '7.5.1', 'Criteria for discontinuation of treatment (\"off treatment\")', 'The following will result in treatment discontinuation:', 'Subject withdraws consent from the study treatment and/or study procedures.', 'Diagnosis of progression, per the discretion of the treating physician. The protocol', 'suggests defining progression based on radiographic or clinical progression and not', 'PSA only progression.', \"AEs or intercurrent illness that in the opinion of the investigator warrants the subject's\", 'withdrawal from study treatment.', 'Significant noncompliance with the protocol schedule or treatment administration in', 'the opinion of the investigator.', '7.5.2', 'Criteria for discontinuation of study (\"off study\")', 'Subjects will be taken off study for the following:', 'Page 25 of 52']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Completed study follow-up period', 'Participant requests to be withdrawn from study', 'Death', 'Subject is lost to follow-up', '8', 'TOXICITIES AND DOSEAGE MODIFICATION', 'This study will utilize the CTCAE (NCI Common Terminology Criteria for Adverse Events)', 'Version 5.0 for adverse event and serious adverse event reporting.', '8.1', 'Dose Modifications and Guidelines for Adverse Event Management', '8.1.1', 'Dose Modifications', 'Dose adjustments for ADT, docetaxel, and abiraterone will be left to the discretion of treating', 'investigator. Toxicities should be monitored and managed per institutional practice.', '8.2', 'Supportive Care', 'All supportive measures consistent with optimal patient care may be given throughout the', 'study.', '8.3', 'Contraception', 'For this trial, male subjects will be considered to be of non-reproductive potential if they have', 'azoospermia (whether due to having had a vasectomy or due to an underlying medical', 'condition).', 'Male subjects of reproductive potential must agree to avoid impregnating a partner while', 'receiving study drug and for 3 months after the last dose of study drug by complying with one', 'of the following:', '(1) practice abstinence from heterosexual activity;', 'OR', '(2) use (or have their partner use) acceptable contraception during heterosexual activity.', 'Acceptable methods of contraception are+:', 'Single method (one of the following is acceptable):', 'intrauterine device (IUD)', 'contraceptive rod implanted into the skin', 'Combination method (requires use of two of the following):', 'diaphragm with spermicide (cannot be used in conjunction with cervical', 'cap/spermicide)', 'cervical cap with spermicide (nulliparous women only)', 'contraceptive sponge (nulliparous women only)', 'male condom or female condom (cannot be used together)', 'Page 26 of 52']\n\n###\n\n", "completion": "END"}